BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Tremelimumab: trial readouts and FDA decisions

2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 3 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, AbbVie. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2AstraZeneca AZNNCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaHepatocellular Carcinomaactive not recruiting114
2027-01 est.P2/P3AbbVie ABBVNCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as aHepatocellular Carcinomaactive not recruiting89

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-27 est.P2AstraZeneca AZNNCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With ChemotherapCarcinoma, Non-Small-Cell Lungactive not recruiting103
2026-09-30 est.P3AstraZeneca AZNNCT05557838 Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCHepatocellular Carcinomaactive not recruiting214
2026-06-01P3AstraZeneca AZNNCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Canceractive not recruiting1246

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.